{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:37:06Z","timestamp":1790318226793,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"\n Objective:<\/jats:title>\n To verify the incidence of bleeding events in patients on ongoing anticoagulant treatment in the real world and compare the results of different reversal or repletion strategies currently available for pharmacological treatment.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Patients managed in the emergency department (ED) with major bleeding events, on ongoing anticoagulation were stratified according to bleeding site and reversal or repletion therapy with andexanet alfa (ADX), idarucizumab (IDA), prothrombin complex concentrate (PCC), and vitamin K (Vit-K).<\/jats:p>\n <\/jats:sec>\n \n Endpoint:<\/jats:title>\n Death at 30 days was compared in the subgroups with cerebral hemorrhage (CH) and gastrointestinal (GI) bleeding.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Of the 809,397 visits in the years 2022\u20132023 at 6 EDs in the northwestern health district of Tuscany, 5372 patients with bleeding events were considered; 3740 were excluded due to minor bleeding or propensity score matching. Of the remaining 1632 patients with major bleeding, 548 on ongoing anticoagulation were enrolled; 334 received reversal or repletion agents. Patients with CH (n = 176) and GI bleeding (n = 108) represented the primary analysis cohorts in the study\u2019s strategic treatment assessment. Overall, 30-day survival of patients on ongoing aFXa treatment receiving on-label ADX versus off-label PCC showed a relative increase of 71%, while 30-day survival of patients on ongoing aFII receiving on-label IDA versus off-label PCC showed a relative increase of 30%; no substantial difference was found when comparing on-label PCC combined with Vit-K versus off-label Vit-K alone. Indeed, patients undergoing on-label ADX or IDA showed a statistically significant difference over off-label PCC (ADX vs. PCC: n = 15, events = 4, mean \u00b1 SD 82.50\u2009\u00b1\u200918.9, vs. 49, 13, 98.82\u2009\u00b1\u200927, respectively; analysis of variance [ANOVA] variance 8627; P<\/jats:italic> < 0.001; posthoc test diff 32, 95% confidence interval: 28\u201335; P<\/jats:italic> < 001; IDA vs. PCC: 20, 5, 32.29\u2009\u00b1\u200915.0 vs. 2, 1, 28.00\u2009\u00b1\u20090.0, respectively; ANOVA 1484; P<\/jats:italic> < 0.001; posthoc test \u221229, \u221229 \u221229, respectively; P<\/jats:italic> = n.d.). On-label PCC combined with Vit-K showed overall a slight statistically significant difference versus off-label Vit-K alone (52, 16, 100.58\u2009\u00b1\u200922.6 vs. 53, 11, 154.62\u2009\u00b1\u200929.8, respectively; ANOVA 310; P<\/jats:italic> < 0.02; posthoc test 4, 0.7\u20137.2, respectively; P<\/jats:italic> < 0.02). Data were confirmed in the group of patients with CH (ADX vs. PCC: n = 13, events = 3, mean \u00b1 SD 91.55\u2009\u00b1\u200918.6 vs. 78, 21, 108.91\u2009\u00b1\u200920.9, respectively; ANOVA variance 10,091, F<\/jats:italic> = 261; P<\/jats:italic> < 0.001; posthoc difference test 36, 95% confidence interval: 30\u201341; P<\/jats:italic> < 0.001; IDA vs. PCC: 10, 2, 4.50\u2009\u00b1\u20092.5 vs. 78, 21, 108.91\u2009\u00b1\u200920.9, respectively; ANOVA 16,876,303, respectively; P<\/jats:italic> < 0.001; posthoc test 41, 34\u201347, respectively; P<\/jats:italic> < 0.001). On-label PCC combined with Vit-K showed an overall slight statistically significant difference compared with off-label Vit-K alone (P<\/jats:italic> < 0.01 and P<\/jats:italic> < 0.001 in the subgroups of CH and GI bleeding).<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Patients undergoing specific reversal therapy with on-label ADX or IDA, when treated with aFXa or aFII anticoagulants, respectively, showed statistically elevated differences in 30-day death compared with off-label repletion therapy with PCC. Overall, 30-day survival of patients on ongoing aFXa or aFII receiving on-label reversal therapy with ADX or IDA compared with off-label PCC repletion agents showed an increase of 71% and 30%, respectively.<\/jats:p>\n <\/jats:sec>","DOI":"10.1097\/hpc.0000000000000360","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T20:01:30Z","timestamp":1718395290000},"page":"58-72","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Reversal or Repletion Treatment Strategies and Outcomes of Patients With Major Bleeding Events Managed in the Emergency Department: Large Real-Life Investigation in the Northwestern Healthcare District of Tuscany"],"prefix":"10.1097","volume":"23","author":[{"given":"Alberto","family":"Conti","sequence":"first","affiliation":[{"name":"From the Emergency Department, Apuane General Hospital, Massa-Carrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Leorin","sequence":"additional","affiliation":[{"name":"From the Emergency Department, Apuane General Hospital, Massa-Carrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Carlotta","family":"Bogazzi","sequence":"additional","affiliation":[{"name":"From the Emergency Department, Apuane General Hospital, Massa-Carrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Renzi","sequence":"additional","affiliation":[{"name":"From the Emergency Department, Apuane General Hospital, Massa-Carrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pepe","sequence":"additional","affiliation":[{"name":"Emergency Department, Versilia and San Luca Hospital, Lucca, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Frosini","sequence":"additional","affiliation":[{"name":"Emergency Department, Versilia and San Luca Hospital, Lucca, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Furesi","sequence":"additional","affiliation":[{"name":"Emergency Department, Pontedera, Livorno and Cecina Hospital, Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Dalla Tomasina","sequence":"additional","affiliation":[{"name":"Emergency Department, Pontedera, Livorno and Cecina Hospital, Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pennati","sequence":"additional","affiliation":[{"name":"Emergency Department, Pontedera, Livorno and Cecina Hospital, Livorno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Ghiadoni","sequence":"additional","affiliation":[{"name":"Emergency Medicine, University of Pisa, Cisanello University Hospital, Pisa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the REVERBLEED Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"R1-20250506","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal.","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20250506","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal. full cohort analysis.","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250506","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity.","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20250506","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors.","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-20250506","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine.","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"R6-20250506","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","article-title":"The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.","volume":"164","author":"Rosand","year":"2004","journal-title":"Arch Intern Med"},{"key":"R7-20250506","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/01.WNL.0000138428.40673.83","article-title":"Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage.","volume":"63","author":"Flibotte","year":"2004","journal-title":"Neurology"},{"key":"R8-20250506","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R9-20250506","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/jth.13148","article-title":"Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH.","volume":"14","author":"Khorsand","year":"2016","journal-title":"J Thromb Haemost"},{"key":"R10-20250506","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R11-20250506","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).","volume":"34","author":"Ryd\u00e9n","year":"2013","journal-title":"Eur Heart J"},{"key":"R12-20250506","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"R13-20250506","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/HPC.0000000000000181","article-title":"Management of severe bleeding in patients treated with oral anticoagulants: Proceedings monograph from the emergency medicine cardiac research and education group-international multidisciplinary severe bleeding consensus panel October 20, 2018.","volume":"18","author":"Gibler","year":"2019","journal-title":"Crit Pathw Cardiol"},{"key":"R14-20250506","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjmed.2010.05.007","article-title":"Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation.","volume":"124","author":"Lip","year":"2011","journal-title":"Am J Med"},{"key":"R15-20250506","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R16-20250506","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.thromres.2023.05.020","article-title":"Idarucizumab for dabigatran reversal: a systematic review and meta-analysis of indications and outcomes.","volume":"228","author":"van der Horst","year":"2023","journal-title":"Thromb Res"},{"key":"R17-20250506","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study.","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"R18-20250506","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants.","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R19-20250506","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annemergmed.2019.09.001","article-title":"Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel.","volume":"76","author":"Baugh","year":"2020","journal-title":"Ann Emerg Med"},{"key":"R20-20250506","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.thromres.2012.10.001","article-title":"Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?.","volume":"130","author":"Voils","year":"2012","journal-title":"Thromb Res"},{"key":"R21-20250506","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1160\/TH11-01-0052","article-title":"Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. a meta-analysis.","volume":"106","author":"Dentali","year":"2011","journal-title":"Thromb Haemost"},{"key":"R22-20250506","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","article-title":"Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage.","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann Neurol"},{"key":"R23-20250506","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"R24-20250506","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","article-title":"Real-world clinical outcomes among US Veterans with oral factor Xa inhibitor\u2013related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate.","volume":"56","author":"Sutton","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"R25-20250506","doi-asserted-by":"crossref","first-page":"102192","DOI":"10.1016\/j.rpth.2023.102192","article-title":"Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.","volume":"7","author":"Dobesh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"R26-20250506","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/bjs.10497","article-title":"Effectiveness of early administration of tranexamic acid in patients with severe trauma.","volume":"104","author":"Shiraishi","year":"2017","journal-title":"Br J Surg"},{"key":"R27-20250506","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCOUTCOMES.108.790634","article-title":"Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review.","volume":"1","author":"Austin","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R28-20250506","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cjca.2015.05.015","article-title":"A review of propensity-score methods and their use in cardiovascular research.","volume":"32","author":"Deb","year":"2016","journal-title":"Can J Cardiol"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T19:02:19Z","timestamp":1746558139000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HPC.0000000000000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/hpc.0000000000000360","relation":{},"ISSN":["1535-2811"],"issn-type":[{"value":"1535-2811","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}